Business Wire

Phenom Named Strategic Leader in Fosway 9-Grid™ for Talent Acquisition 2024 for Fourth Consecutive Year

Share

Phenom has been named a Strategic Leader in the 2024 Fosway 9-Grid™ for Talent Acquisition for the fourth consecutive year, demonstrating the comprehensive nature of its solution and its ability to innovate, drive business impact, and support with customer adoption and satisfaction compared to alternative talent acquisition software solutions. Fosway identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sophistication to consistently meet the needs of complex enterprise-scale customers. Strategic Leaders are also recognised by Fosway for having strong market performance and customer advocacy; as a result, they are frequently selected by such organisations and consistently meet their needs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530551981/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Phenom has been named a Strategic Leader in the 2024 Fosway 9-Grid™ for Talent Acquisition for the fourth consecutive year, demonstrating the comprehensive nature of its solution and its ability to innovate, drive business impact, and support with customer adoption and satisfaction compared to alternative talent acquisition software solutions. (Graphic: Business Wire)

The European job market is undergoing a significant transformation. Challenges such as talent shortages and technological disruptions are actively shaping the dynamics of recruitment practices. To navigate this, talent acquisition leaders, sourcers, talent marketers, recruitment events managers, and recruiters must adopt a multifaceted approach that encompasses building alliances, appropriately leveraging and consolidating technology, personalising candidate engagement, maximising utilisation of artificial intelligence and automation, and embracing data insights.

“The TA industry faces many challenges due to a fragmented tech stack, and companies often struggle to streamline their recruitment processes and engage candidates effectively,” said David Wilson, CEO and founder of Fosway Group. “Phenom’s Intelligent Talent Experience platform aims to deliver an effective, data-driven, personalised enterprise solution to these issues. Their continued innovation and customer outcomes are reflected in their position as a Strategic Leader for a fourth successive year.”

The Most Productive, Efficient Organisations Will Define the Decade Ahead

More than 600 global, diverse enterprises use Phenom’s automations, intelligence, and experience to achieve measurable, defensible results, including the ability to:

“Phenom's fourth consecutive year being recognised as a Strategic Leader in the 2024 Fosway 9-Grid™ for Talent Acquisition reaffirms our commitment to innovation, customer impact, and advocacy,” said John Harrington, Senior Director, Product Marketing at Phenom. “Securing the highest positioning in performance and potential is a testament to our 13+ years in the industry and reflects our ability to partner with global organisations across all industries to address their unique challenges and exceed their goals.”

Leading the Way in Generative AI Adoption and Impact in HR

The advent of generative AI in the past year afforded Phenom a significant opportunity to address the challenges being experienced by its customers with immediate solutions that drive efficiency and productivity outcomes. Since its introduction in 2023, Phenom X+ Generative AI in Phenom’s Intelligent Talent Experience platform has been adopted by over 600 customers, supporting over 60 use cases, and saving HR teams 37,000 hours in the process. Top X+ generative AI use cases and examples of time savings include:

  • Email generation, saving Talent CRM users over 6 minutes per email
  • Generation of profile summaries, affording 15 hours back to talent acquisition teams each week
  • Development of SMS and email campaigns, leading to 35% higher response rates from candidates

Unleashing a Massive Wave of HR Tech Innovation

Phenom continues to innovate by introducing new functionality and capabilities intended to address the top challenges being experienced by talent practitioners today.

2024 Phenom platform innovation highlights include:

  • Talent Experience Engine: transforms talent marketers into strategists by leveraging large datasets to create personalised, on-brand campaigns. It enhances efficiency by unifying persona and journey data, enabling content creation, segment identification, personalised journeys, and automated outreach. This comprehensive set of tools optimises engagement and conversion for candidates, employees, and alumni.
  • X+ Source: optimises sourcing by segmenting talent pools and creating personalised journeys to attract best-fit candidates. Simply request candidates for a specific role and location, and X+ Source finds the best-fit talent, provides recommendations, summarises key details, and conducts automatic outreach to establish initial contact.
  • X+ Workforce Intelligence: connects data from employees, management, HR teams, candidates, and recruiters to provide real-time talent insights for proactive retention and growth. HR teams and managers can identify skills gaps, create personalised development plans, and designate successors based on data to find ideal candidates.
  • Talent Marketer Experience: empowers talent marketers to craft personalised content, design campaigns, segment talent, and engage effectively using AI and automation. X+ Agents guide marketers through tasks, enhancing engagement throughout the talent lifecycle via a single, unified platform.
  • Talent Leader Experience: provides recruitment managers with organisation-wide insights and individual performance data, including requisition and candidate interaction metrics. X+ Agents offer tailored action plans based on hiring type, enhancing team efficiency and effectiveness.
  • X+ Screening: enables fast, intelligent hiring decisions by offering comprehensive insights based on recorded answers, situational judgment questions, and call simulations for all job types.
  • Structured Interviews: streamlines interview processes with automated note-taking, question management, and real-time transcription. It enables hiring teams to focus on meaningful candidate interactions while reducing human error and leveraging AI for confident hiring decisions through organised and analysed data.
  • Contingent Talent Hiring: helps top brands attract contractors effortlessly via Phenom. Companies can now seamlessly discover and hire temporary workers, with integrated support for Vendor Management Systems and payroll providers for smooth onboarding.
  • Events Pro: streamlines event creation to easily target demographics through email, SMS, and registration forms. Personalised virtual event lobbies allow talent to review content, visit booths, and receive automatic event summaries via email.
  • Phenom Assessments: have expanded the existing behavioral and language assessments to include motivation and interest assessments to guide early talent to the right jobs.
  • X+ Fit Score: enables talent acquisition professionals to extend the typical criteria used to formulate fit scores, or customise the scores in the context of the role.

Companies across EMEA are successfully adopting Phenom’s Intelligent Talent Experience platform to help candidates find and choose the right job faster, employees develop their skills and evolve, recruiters become wildly productive, talent marketers engage with extreme efficiency, talent leaders optimise hiring processes, managers build stronger-performing teams, HR align employee development with company goals, and HRIS easily integrate existing HR tech to create a holistic infrastructure.

On June 6, Phenom is demonstrating its massive wave of recent platform innovations during its HR Innovation Showcase. Register here for the streaming event and see how Phenom continues to innovate, earning its position as a Strategic Leader for the fourth consecutive year.

About the Fosway 9-Grid™

Fosway Group is Europe’s #1 HR industry analyst. The Fosway 9-Grid™ provides a unique assessment of the principal learning and talent supply options available to organisations in EMEA. The analysis is based on extensive independent research and insights from Fosway’s Corporate Research Network of over 250 organisations, including BP, HSBC, PwC, RBS, Sanofi, Shell, and Vodafone. Visit the Fosway website at www.fosway.com.

About Phenom

Phenom has a purpose of helping a billion people find the right work. Through AI-powered talent experiences, employers use Phenom to hire employees faster, develop them to their full potential, and retain them longer. The Phenom Intelligent Talent Experience platform seamlessly connects candidates, employees, recruiters, talent marketers, talent leaders, hiring managers, HR and HRIS — empowering diverse and global enterprises with innovative products including Phenom X+ Generative AI, Career Site, Chatbot, CMS, Talent CRM, One-Way Interviews, Automated Interview Scheduling, Interview Intelligence, Talent Experience Engine, Campaigns, University Recruiting, Contingent Talent Hiring, Talent Marketplace, Workforce Intelligence, Career Pathing, Gigs, Mentoring, and Referrals.

Phenom has earned accolades including: Inc. 5000’s fastest-growing companies (4 consecutive years), Deloitte Technology's Fast 500 (4 consecutive years), five Brandon Hall ‘Excellence in Technology’ awards including Gold for ‘Best Advance in AI for Business Impact,’ Business Intelligence Group's Artificial Intelligence Excellence Awards (3 consecutive years), and a regional Timmy Award for launching and optimizing HelpOneBillion.com (2020).

Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.

For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, Twitter, Facebook, YouTube and Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Jennifer Lyons
Phenom
267-379-5066
jennifer.lyons@phenom.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release

I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye